Marco Maggiorini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marco Maggiorini has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Robert Naeije
From University Hospital Zürich, Zürich, University Hospital Basel, Basel, and Kantonsspital Chur, Chur, Switzerland; Université de Bruxelles, Brussels, Belgium; and Medical Clinic VII, University of Heidelberg, Heidelberg, Germany
3 shared publications- Christian Mélot
Department of Emergency Medicine, Erasme University Hospital, Brussels, Belgium
2 shared publications Alain Bernheim
From University Hospital Zürich, Zürich, University Hospital Basel, Basel, and Kantonsspital Chur, Chur, Switzerland; Université de Bruxelles, Brussels, Belgium; and Medical Clinic VII, University of Heidelberg, Heidelberg, Germany
1 shared publicationChristoph Dehnert
From University Hospital Zürich, Zürich, University Hospital Basel, Basel, and Kantonsspital Chur, Chur, Switzerland; Université de Bruxelles, Brussels, Belgium; and Medical Clinic VII, University of Heidelberg, Heidelberg, Germany
1 shared publicationClaudio Sartori
From the Medical Intensive Care Unit of the Department of Internal Medicine (M.M., I.G.), the Division of Nuclear Medicine (F.P.) and the Department of Radiology (M.H.), UniversitätsSpital, Zürich, and the Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne (C.S., M.L., U.S.), Switzerland; and the Departments of Intensive Care and Physiology (S.P., C.M., R.N.), Erasme University Hospital, Brussels, Belgium
1 shared publicationDidier De Canniere
Laboratory of Cardiovascular and Respiratory Physiology, Erasme University Hospital, B-1070 Brussels, Belgium
1 shared publication
Latest Publications
- 1 May 2010
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 52 (6) , 500-506
Prevention and Treatment of High-Altitude Pulmonary Edema
- 1 May 2010
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 52 (6) , 500-506
Prevention and Treatment of High-Altitude Pulmonary Edema
- 3 October 2006
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 145 (7) , 497-506
Both Tadalafil and Dexamethasone May Reduce the Incidence of High-Altitude Pulmonary Edema
High-altitude pulmonary edema (HAPE) is caused by exaggerated hypoxic pulmonary vasoconstriction associated with decreased bioavailability of nitric oxide in the lungs and by impaired reabsorption of alveolar fluid. To investigate whether dexamethasone or tadalafil reduces the incidence of HAPE and acute mountain sickness (AMS) in adults with a history of HAPE. Randomized, double-blind, placebo-controlled study performed in summer 2003. Ascent from 490 m within 24 hours and stay for 2 nights at 4559 m. 29 adults with previous HAPE. Prophylactic tadalafil (10 mg), dexamethasone (8 mg), or placebo twice daily during ascent and stay at 4559 m. Chest radiography was used to diagnose HAPE. A Lake Louise score greater than 4 defined AMS. Systolic pulmonary artery pressure was measured by using Doppler echocardiography, and nasal potentials were measured as a surrogate marker of alveolar sodium transport. Two participants who received tadalafil developed severe AMS on arrival at 4559 m and withdrew from the study; they did not have HAPE at that time. High-altitude pulmonary edema developed in 7 of 9 participants receiving placebo and 1 of the remaining 8 participants receiving tadalafil but in none of the 10 participants receiving dexamethasone (P = 0.007 for tadalafil vs. placebo; P < 0.001 for dexamethasone vs. placebo). Eight of 9 participants receiving placebo, 7 of 10 receiving tadalafil, and 3 of 10 receiving dexamethasone had AMS (P = 1.0 for tadalafil vs. placebo; P = 0.020 for dexamethasone vs. placebo). At high altitude, systolic pulmonary artery pressure increased less in participants receiving dexamethasone (16 mm Hg [95% CI, 9 to 23 mm Hg]) and tadalafil (13 mm Hg [CI, 6 to 20 mm Hg]) than in those receiving placebo (28 mm Hg [CI, 20 to 36 mm Hg]) (P = 0.005 for tadalafil vs. placebo; P = 0.012 for dexamethasone vs. placebo). No statistically significant difference between groups was found in change in nasal potentials and expression of leukocyte sodium transport protein messenger RNA. The study involved a small sample of adults with a history of HAPE. Both dexamethasone and tadalafil decrease systolic pulmonary artery pressure and may reduce the incidence of HAPE in adults with a history of HAPE. Dexamethasone prophylaxis may also reduce the incidence of AMS in these adults. ClinicalTrials.gov identifier: NCT00274430.
- 3 October 2006
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 145 (7) , 497-506
Both Tadalafil and Dexamethasone May Reduce the Incidence of High-Altitude Pulmonary Edema
High-altitude pulmonary edema (HAPE) is caused by exaggerated hypoxic pulmonary vasoconstriction associated with decreased bioavailability of nitric oxide in the lungs and by impaired reabsorption of alveolar fluid. To investigate whether dexamethasone or tadalafil reduces the incidence of HAPE and acute mountain sickness (AMS) in adults with a history of HAPE. Randomized, double-blind, placebo-controlled study performed in summer 2003. Ascent from 490 m within 24 hours and stay for 2 nights at 4559 m. 29 adults with previous HAPE. Prophylactic tadalafil (10 mg), dexamethasone (8 mg), or placebo twice daily during ascent and stay at 4559 m. Chest radiography was used to diagnose HAPE. A Lake Louise score greater than 4 defined AMS. Systolic pulmonary artery pressure was measured by using Doppler echocardiography, and nasal potentials were measured as a surrogate marker of alveolar sodium transport. Two participants who received tadalafil developed severe AMS on arrival at 4559 m and withdrew from the study; they did not have HAPE at that time. High-altitude pulmonary edema developed in 7 of 9 participants receiving placebo and 1 of the remaining 8 participants receiving tadalafil but in none of the 10 participants receiving dexamethasone (P = 0.007 for tadalafil vs. placebo; P < 0.001 for dexamethasone vs. placebo). Eight of 9 participants receiving placebo, 7 of 10 receiving tadalafil, and 3 of 10 receiving dexamethasone had AMS (P = 1.0 for tadalafil vs. placebo; P = 0.020 for dexamethasone vs. placebo). At high altitude, systolic pulmonary artery pressure increased less in participants receiving dexamethasone (16 mm Hg [95% CI, 9 to 23 mm Hg]) and tadalafil (13 mm Hg [CI, 6 to 20 mm Hg]) than in those receiving placebo (28 mm Hg [CI, 20 to 36 mm Hg]) (P = 0.005 for tadalafil vs. placebo; P = 0.012 for dexamethasone vs. placebo). No statistically significant difference between groups was found in change in nasal potentials and expression of leukocyte sodium transport protein messenger RNA. The study involved a small sample of adults with a history of HAPE. Both dexamethasone and tadalafil decrease systolic pulmonary artery pressure and may reduce the incidence of HAPE in adults with a history of HAPE. Dexamethasone prophylaxis may also reduce the incidence of AMS in these adults. ClinicalTrials.gov identifier: NCT00274430.
- 1 October 2006
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 72 (1) , 41-50
High altitude-induced pulmonary oedema
Almost one mountain trekker or climber out of two develops several symptoms of high altitude illness after a rapid ascent (> 300 m/day) to an altitude above 4000 m. Individual susceptibility is the most important determinant for the occurrence of high altitude pulmonary oedema (HAPE). Symptoms associated with HAPE are incapacitating fatigue, chest tightness, dyspnoea at the slightest effort, orthopnoea, and cough with due to haemoptysis in an advanced stage of the disease pink frothy sputum. The hallmark of HAPE is an excessively elevated pulmonary artery pressure (mean pressures of 35 and 55 mm Hg), which precedes the development of pulmonary oedema. Elevated pulmonary capillary pressure and protein- as well as red blood cell-rich oedema fluid without signs of inflammation in its early stage are characteristic findings. Furthermore, decreased fluid clearance from the alveoli may contribute to this non-cardiogenic pulmonary oedema. Immediate descent or supplemental oxygen and nifedipine are recommended until descent is possible. Susceptible individuals can prevent HAPE by slow ascent: an average gain of altitude not exceeding 400 m/day above an altitude of 2500 m. If progressive high altitude acclimatization is not possible, a prophylaxis with nifedipine should be recommended.
- 1 October 2006
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 72 (1) , 41-50
High altitude-induced pulmonary oedema
Almost one mountain trekker or climber out of two develops several symptoms of high altitude illness after a rapid ascent (> 300 m/day) to an altitude above 4000 m. Individual susceptibility is the most important determinant for the occurrence of high altitude pulmonary oedema (HAPE). Symptoms associated with HAPE are incapacitating fatigue, chest tightness, dyspnoea at the slightest effort, orthopnoea, and cough with due to haemoptysis in an advanced stage of the disease pink frothy sputum. The hallmark of HAPE is an excessively elevated pulmonary artery pressure (mean pressures of 35 and 55 mm Hg), which precedes the development of pulmonary oedema. Elevated pulmonary capillary pressure and protein- as well as red blood cell-rich oedema fluid without signs of inflammation in its early stage are characteristic findings. Furthermore, decreased fluid clearance from the alveoli may contribute to this non-cardiogenic pulmonary oedema. Immediate descent or supplemental oxygen and nifedipine are recommended until descent is possible. Susceptible individuals can prevent HAPE by slow ascent: an average gain of altitude not exceeding 400 m/day above an altitude of 2500 m. If progressive high altitude acclimatization is not possible, a prophylaxis with nifedipine should be recommended.
- 1 December 2003
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 22 (6) , 1019-1025
High-altitude pulmonary hypertension: a pathophysiological entity to different diseases
Pulmonary hypertension is a hallmark of high-altitude pulmonary oedema (HAPE) and of congestive right heart failure in subacute mountain sickness (SMS) and chronic mountain sickness (CMS) in the Himalayas and in the end-stage of CMS (Monge's disease) in the Andes.There are studies to suggest that transmission of excessively elevated pulmonary artery pressure and/or flow to the pulmonary capillaries leading to alveolar haemorrhage is the pathophysiological mechanism of HAPE.In the Himalayas, HAPE was successfully prevented by extending the acclimatisation period from a few days to 5 weeks, however, this did not prevent the occurrence of congestive right heart failure after several weeks of stay at 6,000 m. This leads to the concept that rapid remodelling of the small precapillary arteries prevents HAPE but not the development of right heart failure in SMS and CMS.Unresponsiveness of pulmonary hypertension to oxygen at high altitude and its complete resolution only after weeks of stay at low altitude suggest that structural rather than functional changes are its pathophysiological mechanism. Since pulmonary hypertension at high altitude is the driving force leading to high-altitude pulmonary oedema and “high-altitude right heart failure” in newcomers and residents of high altitude, the authors propose to adjust current terminology accordingly.
- 1 December 2003
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 22 (6) , 1019-1025
High-altitude pulmonary hypertension: a pathophysiological entity to different diseases
Pulmonary hypertension is a hallmark of high-altitude pulmonary oedema (HAPE) and of congestive right heart failure in subacute mountain sickness (SMS) and chronic mountain sickness (CMS) in the Himalayas and in the end-stage of CMS (Monge's disease) in the Andes.There are studies to suggest that transmission of excessively elevated pulmonary artery pressure and/or flow to the pulmonary capillaries leading to alveolar haemorrhage is the pathophysiological mechanism of HAPE.In the Himalayas, HAPE was successfully prevented by extending the acclimatisation period from a few days to 5 weeks, however, this did not prevent the occurrence of congestive right heart failure after several weeks of stay at 6,000 m. This leads to the concept that rapid remodelling of the small precapillary arteries prevents HAPE but not the development of right heart failure in SMS and CMS.Unresponsiveness of pulmonary hypertension to oxygen at high altitude and its complete resolution only after weeks of stay at low altitude suggest that structural rather than functional changes are its pathophysiological mechanism. Since pulmonary hypertension at high altitude is the driving force leading to high-altitude pulmonary oedema and “high-altitude right heart failure” in newcomers and residents of high altitude, the authors propose to adjust current terminology accordingly.
- 1 June 2001
- Published by Hogrefe Publishing Group in Therapeutische Umschau
- Vol. 58 (6) , 387-393
Trekking and high altitude illness
Jeder zweite Trecker oder Bergsteiger, der rasch (> 300 m/Tag) auf Höhen über 4000 m steigt, hat nach 6 bis 12 Stunden Symptome der Höhenkrankheit. Wir unterscheiden zwei Formen der Höhenkrankheit: die akute Bergkrankheit und das Höhenlungenödem. Die milde und benigne Form der akuten Bergkrankheit äußert sich mit Kopfschmerzen, Appetitlosigkeit, Übelkeit, seltener mit Erbrechen, Schwindelgefühl und Schlaflosigkeit. Die schwere und maligne Form der akuten Bergkrankheit wird Höhenhirnödem genannt und präsentiert sich mit den Symptomen der milden akuten Bergkrankheit mit einer zusätzlichen Gangataxie bis zur Stehunfähigkeit und/oder einer Beeinträchtigung des Bewusstseins bis zum Koma. Die Ursache der akuten Bergkrankheit ist eine zerebrale Dysfunktion, die pathophysiologischen Mechanismen bleiben aber unklar. Das Höhenlungenödem gehört zur Höhenkrankheit, unterscheidet sich aber pathophysiologisch von der akuten Bergkrankheit. Das Höhenlungenödem präsentiert sich klinisch mit stark eingeschränkter Leistungsfähigkeit und Müdigkeit, retrosternalem Druckgefühl, Atemnot, Orthopnoe, Husten, Rasseln in den Atemwegen und blutig tingiertem Auswurf. Pathognomonisch für das Höhenlungen-ödem ist eine Hypoxie-induzierte schwere pulmonal-arterielle Hypertonie. Zweidrittel der Patienten mit Höhenlungenödem hat wegen der schweren Hypoxämie Symptome der malignen akuten Bergkrankheit. Die Behandlung der Höhenkrankheit besteht primär in der Beseitigung der Hypoxie. Acetazolamid (Diamox®), ein Karboanhydrasehemmer, stimuliert die Ventilation und eliminiert die für die Höhe charakteristische periodische Atmung, es eignet sich gut für die Prophylaxe und Behandlung der benignen akuten Bergkrankheit. Die schwere akute Bergkrankheit wird mit Dexamethason (Decadron®) behandelt. Nifedipin (Adalat®), ein wirksamer pulmonaler Vasodilatator, ist das Medikament erster Wahl zur Prophylaxe und Behandlung des Höhenlungenödems.
- 1 June 2001
- Published by Hogrefe Publishing Group in Therapeutische Umschau
- Vol. 58 (6) , 387-393
Trekking and high altitude illness
Jeder zweite Trecker oder Bergsteiger, der rasch (> 300 m/Tag) auf Höhen über 4000 m steigt, hat nach 6 bis 12 Stunden Symptome der Höhenkrankheit. Wir unterscheiden zwei Formen der Höhenkrankheit: die akute Bergkrankheit und das Höhenlungenödem. Die milde und benigne Form der akuten Bergkrankheit äußert sich mit Kopfschmerzen, Appetitlosigkeit, Übelkeit, seltener mit Erbrechen, Schwindelgefühl und Schlaflosigkeit. Die schwere und maligne Form der akuten Bergkrankheit wird Höhenhirnödem genannt und präsentiert sich mit den Symptomen der milden akuten Bergkrankheit mit einer zusätzlichen Gangataxie bis zur Stehunfähigkeit und/oder einer Beeinträchtigung des Bewusstseins bis zum Koma. Die Ursache der akuten Bergkrankheit ist eine zerebrale Dysfunktion, die pathophysiologischen Mechanismen bleiben aber unklar. Das Höhenlungenödem gehört zur Höhenkrankheit, unterscheidet sich aber pathophysiologisch von der akuten Bergkrankheit. Das Höhenlungenödem präsentiert sich klinisch mit stark eingeschränkter Leistungsfähigkeit und Müdigkeit, retrosternalem Druckgefühl, Atemnot, Orthopnoe, Husten, Rasseln in den Atemwegen und blutig tingiertem Auswurf. Pathognomonisch für das Höhenlungen-ödem ist eine Hypoxie-induzierte schwere pulmonal-arterielle Hypertonie. Zweidrittel der Patienten mit Höhenlungenödem hat wegen der schweren Hypoxämie Symptome der malignen akuten Bergkrankheit. Die Behandlung der Höhenkrankheit besteht primär in der Beseitigung der Hypoxie. Acetazolamid (Diamox®), ein Karboanhydrasehemmer, stimuliert die Ventilation und eliminiert die für die Höhe charakteristische periodische Atmung, es eignet sich gut für die Prophylaxe und Behandlung der benignen akuten Bergkrankheit. Die schwere akute Bergkrankheit wird mit Dexamethason (Decadron®) behandelt. Nifedipin (Adalat®), ein wirksamer pulmonaler Vasodilatator, ist das Medikament erster Wahl zur Prophylaxe und Behandlung des Höhenlungenödems.
- 24 April 2001
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (16) , 2078-2083
High-Altitude Pulmonary Edema Is Initially Caused by an Increase in Capillary Pressure
Background —High-altitude pulmonary edema (HAPE) is characterized by severe pulmonary hypertension and bronchoalveolar lavage fluid changes indicative of inflammation. It is not known, however, whether the primary event is an increase in pressure or an increase in permeability of the pulmonary capillaries. Methods and Results —We studied pulmonary hemodynamics, including capillary pressure determined by the occlusion method, and capillary permeability evaluated by the pulmonary transvascular escape of 67 Ga-labeled transferrin, in 16 subjects with a previous HAPE and in 14 control subjects, first at low altitude (490 m) and then within the first 48 hours of ascent to a high-altitude laboratory (4559 m). The HAPE-susceptible subjects, compared with the control subjects, had an enhanced pulmonary vasoreactivity to inspiratory hypoxia at low altitude and higher mean pulmonary artery pressures (37±2 versus 26±1 mm Hg, P P 19 mm Hg (range 20 to 26 mm Hg), whereas all 7 susceptible subjects without HAPE had a pulmonary capillary pressure Conclusions —HAPE is initially caused by an increase in pulmonary capillary pressure.
- 24 April 2001
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (16) , 2078-2083
High-Altitude Pulmonary Edema Is Initially Caused by an Increase in Capillary Pressure
Background —High-altitude pulmonary edema (HAPE) is characterized by severe pulmonary hypertension and bronchoalveolar lavage fluid changes indicative of inflammation. It is not known, however, whether the primary event is an increase in pressure or an increase in permeability of the pulmonary capillaries. Methods and Results —We studied pulmonary hemodynamics, including capillary pressure determined by the occlusion method, and capillary permeability evaluated by the pulmonary transvascular escape of 67 Ga-labeled transferrin, in 16 subjects with a previous HAPE and in 14 control subjects, first at low altitude (490 m) and then within the first 48 hours of ascent to a high-altitude laboratory (4559 m). The HAPE-susceptible subjects, compared with the control subjects, had an enhanced pulmonary vasoreactivity to inspiratory hypoxia at low altitude and higher mean pulmonary artery pressures (37±2 versus 26±1 mm Hg, P P 19 mm Hg (range 20 to 26 mm Hg), whereas all 7 susceptible subjects without HAPE had a pulmonary capillary pressure Conclusions —HAPE is initially caused by an increase in pulmonary capillary pressure.
- Open Access
- 1 March 1998
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 84 (3) , 815-821
Effects of pulmonary embolism on pulmonary vascular impedance in dogs and minipigs
Pigs have been reported to present with a stronger pulmonary vascular reactivity than many other species, including dogs. We investigated the pulmonary vascular impedance response to autologous blood clot embolic pulmonary hypertension in anesthetized and ventilated minipigs ( n = 6) and dogs ( n = 6). Before embolization, minipigs, compared with dogs, presented with higher mean pulmonary arterial pressure (Ppa; by an average of 9 mmHg), a steeper slope of Ppa-flow (Q˙) relationships, and higher 0-Hz impedance (Z0) and first-harmonic impedance (Z1), without significant differences in characteristic impedance (Zc), and a lower ratio of pulsatile hydraulic power to total hydraulic power. Embolic pulmonary hypertension (mean Ppa: 40–55 mmHg) was associated with increased Z0 and Z1 in both species, but the minipigs had a steeper slope of Ppa/Q˙ plots and an increased Zc. At identical Q˙ and Ppa, minipigs still presented with higher Z1 and Zc and a lower ratio of pulsatile hydraulic power to total hydraulic power. The energy transmission ratio, defined as the hydraulic power in the measured waves divided by the hydraulic power in the forward waves, was better preserved after embolism in minipigs. No differences in wave reflection indexes were found before and after embolism. We conclude that minipigs, compared with dogs, present with a higher pulmonary vascular resistance and reactivity and adapt to embolic pulmonary hypertension by an increased Zc without earlier wave reflection. These differences allow for a reduced pulsatile component of hydraulic power and, therefore, a better energy transfer from the right ventricle to the pulmonary circulation.
- 1 March 1998
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 84 (3) , 815-821
Open AccessEffects of pulmonary embolism on pulmonary vascular impedance in dogs and minipigs
Pigs have been reported to present with a stronger pulmonary vascular reactivity than many other species, including dogs. We investigated the pulmonary vascular impedance response to autologous blood clot embolic pulmonary hypertension in anesthetized and ventilated minipigs ( n = 6) and dogs ( n = 6). Before embolization, minipigs, compared with dogs, presented with higher mean pulmonary arterial pressure (Ppa; by an average of 9 mmHg), a steeper slope of Ppa-flow (Q˙) relationships, and higher 0-Hz impedance (Z0) and first-harmonic impedance (Z1), without significant differences in characteristic impedance (Zc), and a lower ratio of pulsatile hydraulic power to total hydraulic power. Embolic pulmonary hypertension (mean Ppa: 40–55 mmHg) was associated with increased Z0 and Z1 in both species, but the minipigs had a steeper slope of Ppa/Q˙ plots and an increased Zc. At identical Q˙ and Ppa, minipigs still presented with higher Z1 and Zc and a lower ratio of pulsatile hydraulic power to total hydraulic power. The energy transmission ratio, defined as the hydraulic power in the measured waves divided by the hydraulic power in the forward waves, was better preserved after embolism in minipigs. No differences in wave reflection indexes were found before and after embolism. We conclude that minipigs, compared with dogs, present with a higher pulmonary vascular resistance and reactivity and adapt to embolic pulmonary hypertension by an increased Zc without earlier wave reflection. These differences allow for a reduced pulsatile component of hydraulic power and, therefore, a better energy transfer from the right ventricle to the pulmonary circulation.
- 1 February 1998
- Published by Elsevier in Respiration Physiology
- Vol. 111 (2) , 213-222
Pulmonary vascular resistance in dogs and minipigs—effects of hypoxia and inhaled nitric oxide
- 1 February 1998
- Published by Elsevier in Respiration Physiology
- Vol. 111 (2) , 213-222
Pulmonary vascular resistance in dogs and minipigs—effects of hypoxia and inhaled nitric oxide